MedPage Today) — BOSTON — Treatment with an investigational anti-KIT monoclonal antibody induced clinically meaningful responses in the two most common forms of chronic inducible urticaria, a dose-ranging phase II trial showed.
In patients…
MedPage Today) — BOSTON — Treatment with an investigational anti-KIT monoclonal antibody induced clinically meaningful responses in the two most common forms of chronic inducible urticaria, a dose-ranging phase II trial showed.
In patients…
